Facial Fat Grafting vs SVF-assisted Fat Grafting
Every fact below comes from the two entity pages and their sources. Dimensions both sides record are compared first; the rest are shown side by side.
Medical
Facial Fat GraftingFacial fat grafting transfers the patient's own fat to the face to restore volume in areas such as the cheeks, temples and under-eye region.Updated Sep 20, 2026Medical
SVF-assisted Fat GraftingSVF-assisted fat grafting (a form of cell-assisted lipotransfer) enriches the fat graft with stromal vascular fraction isolated from part of the harvested fat, with the aim of improving graft survival.Updated Sep 21, 2026Shared dimensions
1 recorded on both sides| Predicate | Facial Fat Grafting | SVF-assisted Fat Grafting |
|---|---|---|
| US FDA tissue regulation | Exempt from 21 CFR Part 1271 when tissue is removed from and reimplanted into the same individual during the same surgical procedure (21 CFR 1271.15(b)) | Collagenase digestion to isolate SVF falls outside 'minimal manipulation'; non-enzymatic mechanical point-of-care methods are proposed as possible alternatives |
Facts on each side
Verified facts recorded for only one of the two.
Facial Fat Grafting
Procedure stepsFat is taken from a donor area by liposuction, decanted, centrifuged or otherwise processed, and the purified fat is reinjected where volume is needed
First documented fat graft1893: Gustav Neuber moved fat from the arm to correct scarring around the eye
Standardized techniqueSydney Coleman published standardized protocols for harvesting, processing and injecting fat (structural fat grafting) in the 1990s
Common facial usesFilling hollows under the eyes and nasolabial folds, repairing scars, enhancing the cheekbones, improving skin texture
Typical total facial graft volume10–100
Reported arterial embolism outcomesIn 61 published cases: permanent vision loss in all 26 with ophthalmic artery occlusion, neurological impairment in 8 of 10 with cerebral artery occlusion, and 6 deaths
No reversal agentHyaluronic acid filler can be dissolved with hyaluronidase, but no agent of comparable effect exists for fat emboli
Worldwide facial fat grafting procedures589,494 procedures; 7th most common aesthetic surgical procedure (ISAPS Global Survey 2021, as cited)
AlternativeDermal fillers (temporary, non-surgical)
Specific riskVascular occlusion when injecting near the eyes or nose (rare)
SVF-assisted Fat Grafting
First clinical descriptionYoshimura K et al., 'Cell-assisted lipotransfer for cosmetic breast augmentation', Aesthetic Plast Surg 2008;32(1):48–55; 40 women, maximum follow-up 42 months
Original procedureAbout half of the aspirated fat is processed to isolate fresh SVF, which is recombined with the other half before injection; the fat acts as a living scaffold
Pooled fat survival (2026 meta-analysis)72.78% with enrichment vs 45.28% conventional (SMD 2.44; 95% CI 1.00–3.88); 15 studies, 634 patients; heterogeneity I² = 97.19%
Efficacy by siteFace showed a significant benefit (SMD 2.95); breast reconstruction showed no significant advantage (SMD 0.47); no benefit with water-assisted lipotransfer harvesting
Methodological qualityAbout 62% of included studies rated weak overall; mean follow-up 16.2 months, too short for oncologic conclusions
Comparative study without benefitPeltoniemi et al. 2013 (JPRAS 66:1494–1503): 18 women, MRI at 6 months; graft survival 50% with Celution SVF enrichment vs 54% without, difference not significant
Breast-surgery evidence base11 studies, 336 patients, follow-up 6–42 months; 8 of 11 studies had no control group; only one used a validated patient-reported outcome measure (BREAST-Q)
Reported complications (breast)Calcifications were the most frequently reported complication; none reported as malignant
Preclinical and early clinical findings16 of 18 preclinical studies showed significantly improved retention (1.19- to 4.14-fold); 6 of 7 clinical studies favored CAL; evidence judged low quality
Applicable US FDA guidanceFinal guidance 'Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use', July 2020 (supersedes November 2017 version)
Also calledCell-assisted lipotransfer (CAL)
EvidenceA 2024 systematic review assessed the efficacy of cell-assisted lipotransfer; a 2021 study compared CAL with PRP-assisted lipotransfer
Proposed mechanismStromal cells may support angiogenesis and graft survival (hypothesis under study)